Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Operating Expenses (2023 - 2025)

CG Oncology (CGON) has disclosed Operating Expenses for 3 consecutive years, with $51.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 32.51% year-over-year to $51.0 million, compared with a TTM value of $194.8 million through Dec 2025, up 68.23%, and an annual FY2025 reading of $194.8 million, up 68.23% over the prior year.
  • Operating Expenses was $51.0 million for Q4 2025 at CG Oncology, down from $52.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $52.8 million in Q3 2025 and bottomed at $9.9 million in Q1 2023.
  • Average Operating Expenses over 3 years is $30.5 million, with a median of $27.2 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 131.95% in 2024, then skyrocketed 32.51% in 2025.
  • Year by year, Operating Expenses stood at $19.4 million in 2023, then soared by 98.93% to $38.5 million in 2024, then skyrocketed by 32.51% to $51.0 million in 2025.
  • Business Quant data shows Operating Expenses for CGON at $51.0 million in Q4 2025, $52.8 million in Q3 2025, and $48.7 million in Q2 2025.